Document Detail

Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device.
MedLine Citation:
PMID:  15979436     Owner:  NLM     Status:  MEDLINE    
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Seung-Woon Rha; Pramod K Kuchulakanti; Rajbabu Pakala; Edouard Cheneau; Ellen Pinnow; Rebecca Torguson; Augusto D Pichard; Lowell F Satler; William O Suddath; Kenneth M Kent; Joseph Lindsay; Ron Waksman
Related Documents :
3504356 - Femoropopliteal in situ saphenous vein bypass: technical aspects and factors determinin...
9124906 - Cryopreserved veins in myocardial revascularization: possible mechanism for their incre...
10940116 - Infiltrating basal cell carcinoma in the setting of a venous ulcer.
6837886 - Aggressive surgical management of popliteal artery aneurysms.
23555426 - Balloon-trapped technique for successful opteasefilter retrieval.
21366686 - A sinus of valsalva aneurysm: more complicated than imagined.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-06-27     Completed Date:  2005-08-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  67-70     Citation Subset:  AIM; IM    
Division of Cardiology, Washington Hospital Center, Washington, DC, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anticoagulants / adverse effects,  therapeutic use*
Coronary Artery Disease / surgery*
Heparin / therapeutic use*
Hirudins / adverse effects
Middle Aged
Peptide Fragments / adverse effects,  therapeutic use*
Postoperative Complications / prevention & control*
Recombinant Proteins / adverse effects,  therapeutic use*
Retrospective Studies
Saphenous Vein / transplantation*
Thrombosis / prevention & control*
Treatment Outcome
Reg. No./Substance:
0/Anticoagulants; 0/Antithrombins; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relation between coronary artery calcium and incident chest pain in a community-dwelling screening p...
Next Document:  Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary i...